Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Siccafluid is an ophthalmic gel containing the active ingredient carbomer 974P, a synthetic high-molecular-weight polymer used as a lubricant and tear substitute. It is indicated for the symptomatic treatment of dry eye syndrome (keratoconjunctivitis sicca), providing relief from symptoms such as soreness, burning, irritation, or dryness caused by insufficient tear production. Carbomer 974P forms a transparent, lubricating and moisturizing film on the ocular surface that mimics natural tears and helps maintain hydration by absorbing water and increasing viscosity. This physical barrier temporarily compensates for tear deficiency but does not address underlying disease mechanisms[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on carbomer 974P.